Cite
Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).
MLA
Sharma, Manish R., et al. “Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).” Journal of Clinical Pharmacology, vol. 60, no. 4, Apr. 2020, pp. 444–52. EBSCOhost, https://doi.org/10.1002/jcph.1559.
APA
Sharma, M. R., Mehrotra, S., Gray, E., Wu, K., Barry, W. T., Hudis, C., Winer, E. P., Lyss, A. P., Toppmeyer, D. L., Moreno, A. A., Lad, T. E., Velasco, M., Overmoyer, B., Rugo, H. S., Ratain, M. J., & Gobburu, J. V. (2020). Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). Journal of Clinical Pharmacology, 60(4), 444–452. https://doi.org/10.1002/jcph.1559
Chicago
Sharma, Manish R., Shailly Mehrotra, Elizabeth Gray, Kehua Wu, William T. Barry, Clifford Hudis, Eric P. Winer, et al. 2020. “Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).” Journal of Clinical Pharmacology 60 (4): 444–52. doi:10.1002/jcph.1559.